Brain tumors are the result of abnormal growth of cells within the skull. Primary brain tumors arise from the growth of brain cells, brain blood vessels, cerebral nerves, or meningeal lesions. Tumors can be either benign (non-cancerous) or malignant (cancerous). Brain tumors are extremely diverse, and epidemiological investigations have found that the occurrence of brain tumors is associated with genetic factors, physicochemical factors, and viruses.
Auditory neuroma
Drugs are part of the treatment for auditory neuroma, and some progress has been made in research into systemic drug therapy for auditory neuroma, including antiretroviral (ART) drugs, anti-vascular endothelial growth factor (VEGF) drugs, and, receptor tyrosine kinase (RTK) inhibitors. We contribute to every brain tumor-related research project, including drug development for an auditory neuroma.
Pituitary tumor
There is a growing interest in developing drug therapies for the control of pituitary tumor growth and/or hormone overproduction, and we will help you to better understand the molecular features of pituitary tumor secretion and proliferation mechanisms to provide the best support for research into multiple types of brain tumor disease.
Meningioma
With advances in genomics and the identification of driver mutations, we have helped researchers in this field to progressively advance their research into targeted drugs. Considering the research on new drugs, identifying and understanding new signaling pathways and factors will hopefully provide ideas for drug development.
Glioma
In the tumor microenvironment, the variant immune checkpoint signaling pathway is an important immune escape mechanism. We are actively helping researchers to carry out more in-depth functional studies of multiple targets. In addition, we are also helping customers to actively explore further possibilities regarding combination therapies and vaccines in glioma research.
Craniopharyngioma
We can help customers to analyze the molecular profile of the enzymatic epidermal craniopharyngioma pathway to reveal potentially therapeutically relevant signaling pathways and thus advance the targeting of small molecule inhibitors. We can also help you identify the upregulation of several markers that may represent potential therapeutic targets.
Choroid plexus tumors
We focus on choroid plexus tumorigenesis and progression, and we seek to provide you with deeper insights and accelerate your research in this area through a variety of solutions, including choroid plexus carcinoma mouse model, gene decoding, and genetic evaluation and, sequencing.
Alfa Cytology actively builds brain tumor biospecimen libraries, digital case repositories, and multi-level basic research platforms including histopathology, molecular pathology, genomics, transcriptomics, and proteomics for our customers. We actively use gene microarray, sequencing, and mass spectrometry technologies to help our customers conduct in-depth studies of brain tumor molecular networks at the DNA, RNA, and protein levels, and to help them model the molecular regulatory networks of gliomas and pituitary adenomas. Please feel free to contact us for more information on primary brain tumors.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Resources
